Evidence map›Paper›PMID 32117302›Full record

ArticleFrontiers in immunology2020

Commentary: Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation.

Alexander B Sigalov

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. TREM-1 Modulation Strategies for Sepsis.Frontiers in immunology · 2022
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alexander B SigalovSignaBlok, Inc., Shrewsbury, MA, United States.
SignaBlok (United States) · US

Funding

First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancerR44CA217400 · NCI · SIGNABLOK, INC. · PI SIGALOV, ALEXANDER B · 2019 to 2020
$2.0M
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancerR43CA217400 · NCI · SIGNABLOK, INC. · PI SIGALOV, ALEXANDER B · 2017 to 2019
$227k
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseasesR43EY028779 · NEI · SIGNABLOK, INC. · PI SIGALOV, ALEXANDER B · 2018 to 2018
$226k
Novel TREM-1 targeting therapies for sepsisR43GM128369 · NIGMS · SIGNABLOK, INC. · PI SIGALOV, ALEXANDER B · 2018 to 2018
$225k
NCI NIH HHS R43 CA217400NCI NIH HHS R44 CA217400NEI NIH HHS R43 EY028779NIGMS NIH HHS R43 GM128369
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Membrane GlycoproteinsMyeloid CellsEndotheliumTriggering Receptor Expressed on Myeloid Cells-1Membrane GlycoproteinsTriggering Receptor Expressed on Myeloid Cells-1ligand-independent inhibitionSCHOOL model of receptor signalingsepsisTREM-1TREM-1 inhibitory SCHOOL peptides

Identifiers

PMID32117302
PMCPMC7026307
OpenAlexW3005996142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.